Not logged inA phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Kondo, S.; Koyama, T.; Kawazoe, A.; Iwasa, S.; Yonemori, K.; Shitara, K.; Nakamura, Y.; Saori, M.; Yamamoto, N.; Sato, J.; Sahara, T.; Hayata, N.; Yamamuro, S.; Kimura, T.; Dutta, L.; Tamai, T.; Ikeda, M. .png)
Share.png)
SaveShare Save Share Save Increased membrane HER3 expression in brain metastases compared to primary tumors in breast cancerKusuhara, S.; Kogawa, T.; Shimokawa, M.; Funasaka, C.; Kondoh, C. N.; Harano, K.; Matsubara, N.; Naito, Y.; Hosono, A.; Satomi, K.; Yoshida, M.; Fujii, S.; Ohnishi, T.; Suto, A.; Yonemori, K.; Koyama, K.; Maeda, N.; Narita, Y.; Mukohara, T. Share Save Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalationTamura, K.; Shitara, K.; Naito, Y.; Shimomura, A.; Fujiwara, Y.; Yonemori, K.; Shimizu, C.; Shimoi, T.; Kuboki, Y.; Matsubara, N.; Kitano, A.; Jikoh, T.; Fujisaki, Y.; Yver, A.; Doi, T. Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
